Travere Therapeutics (TVTX) Equity Ratio: 2011-2025
Historic Equity Ratio for Travere Therapeutics (TVTX) over the last 14 years, with Sep 2025 value amounting to 0.14.
- Travere Therapeutics' Equity Ratio rose 326.23% to 0.14 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.14, marking a year-over-year increase of 326.23%. This contributed to the annual value of 0.10 for FY2024, which is 60.94% down from last year.
- As of Q3 2025, Travere Therapeutics' Equity Ratio stood at 0.14, which was up 131.62% from 0.06 recorded in Q2 2025.
- Travere Therapeutics' Equity Ratio's 5-year high stood at 0.47 during Q1 2021, with a 5-year trough of -0.06 in Q3 2024.
- Its 3-year average for Equity Ratio is 0.13, with a median of 0.11 in 2024.
- Per our database at Business Quant, Travere Therapeutics' Equity Ratio tumbled by 117.97% in 2024 and then surged by 326.23% in 2025.
- Over the past 5 years, Travere Therapeutics' Equity Ratio (Quarterly) stood at 0.39 in 2021, then tumbled by 83.62% to 0.06 in 2022, then surged by 299.52% to 0.25 in 2023, then tumbled by 60.94% to 0.10 in 2024, then surged by 326.23% to 0.14 in 2025.
- Its Equity Ratio was 0.14 in Q3 2025, compared to 0.06 in Q2 2025 and 0.06 in Q1 2025.